key: cord-0899965-nquibkqi
authors: Chauhan, Nidhi; Soni, Shringika; Gupta, Abhinandan; Aslam, Mohammad; Jain, Utkarsh
title: Interpretative immune targets and contemporary position for vaccine development against SARS‐CoV‐2: A systematic review
date: 2020-12-17
journal: J Med Virol
DOI: 10.1002/jmv.26709
sha: 51944bc1eb08e3ce7721af5842ad6ab3fbff2d15
doc_id: 899965
cord_uid: nquibkqi

The year 2020 started with the emergence of novel coronavirus, severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), which causes COVID‐19 infection. Soon after the first evidence was reported in Wuhan, China, the World Health Organization declared global public health emergency and imminent need to understand the pathogenicity of the virus was required in limited time. Once the genome sequence of the virus was delineated, scientists across the world started working on the development of vaccines. Although, some laboratories have been using previously developed vaccine platforms from severe acute respiratory syndrome coronavirus (SARS) and middle east respiratory syndrome‐related coronavirus and apply them in COVID‐19 vaccines due to genetic similarities between coronaviruses. We have conducted a literature review to assess the background and current status of COVID‐19 vaccines. The worldwide implementation and strategies for COVID‐19 vaccine development are summarized from studies reported in years 2015–2020. While discussing the vaccine candidates, we have also explained interpretative immune responses of SARS‐CoV‐2 infection. There are several vaccine candidates at preclinical and clinical stages; however, only 42 vaccines are under clinical trials. Therefore, more industry collaborations and financial supports to COVID‐19 studies are needed for mass‐scale vaccine development. To develop effective vaccine platforms against SARS‐CoV‐2, the genetic resemblance with other coronaviruses are being evaluated which may further promote fast‐track trials on previously developed SARS‐CoV vaccines.

cases and more than 1.06 million deaths due to COVID-19 are reported in more than 210 countries and territories. 4 The collaborative efforts of WHO and scientist's community across various countries are evaluating the pathogenesis of COVID-19 and their signaling pathways to target biomarkers for controlling, preventing, and developing new therapeutics against SARS-CoV-2 infection.

The SARS-CoV-2 is positive-sense single-strand RNA (26-32 kb) coronavirus belonging to Coronaviridae family, Coronvirinae subfamily, and Nidovirales order. 5, 6 On the basis of their genetic structure, the coronavirus have been classified into alpha (α), beta (β), gamma (γ), and delta (δ) genera. Among these genera, only αand βcoronavirus infect mammals. 7 By evaluating the complete genome sequence of SARS-CoV-2 coronavirus, it was reported that the virus posses a genetic similarity of 96.2% with bat CoV RaTG13 and 70% with SARS-CoV. [7] [8] [9] Furthermore, similar to other coronaviruses, SARS-CoV-2 also encodes structural proteins, namely nucleocapsid protein (N), envelope protein (E), membrane protein (M), and spike protein (S). 7 Initially, the combination of antiviral drugs, such as chloroquine, remdesivir, favipiravir, and arbidol, along with antibiotics were prescribed for SARS-CoV-2 infection in clinical patients. [15] [16] [17] Randomized clinical trials were studied by administering lopinavir-ritonavir (1:1 ratio) in COVID-19 patients twice a day for 14 days. A similar mortality rate between treated and standard care groups was reported. 18 Severe gastrointestinal adverse effects in the standard care group were noticed, and therefore, treatment was stopped in 13.8% patients. Furthermore, irregular heartbeats and cardiac arrest in patients prescribed with hydroxychloroquine (HCQ) and antibiotic azithromycin against SARS-CoV-2 pneumonia were also reported. 19, 20 Therefore, HCQ was approved by the food and drug administration (FDA) on March 30, 2020, for only hospitalized suspected or confirmed COVID-19 patients under emergency use authorization. 21 On the other hand, convalescent plasma or immunoglobulins based treatment therapy was also provided to COVID-19 patients. It has been previously prescribed in H1N1, HIV-1, and Ebola viral infections. 22 However, plasma therapy is not efficient in end-stage COVID-19 patients. 23 In considering forgoing passive antibodies, a short period of time and their regulatory and logistical challenges limit their use in the current situation. 24 Contemplating various challenges associated with treatment therapies against SARS-CoV-2 coronavirus, while investigating cross-resistance of other vaccines with COVID-19, the new candidates for vaccines have been evaluated. [25] [26] [27] [28] Presently, over a dozen potential candidates including recombinant protein subunits, oligonucleotides, and live viruses are being evaluated against SARS-CoV-2. Besides, more than 100 preclinical studies, 42 clinical trials are being analyzed to develop new and effective vaccine therapy. 29 However, formal testing toxicology study, additional manufacturing steps, and finding volunteers to study COVID-19 specific vaccine are continuously delaying the development. The funds from manufacturers who were previously developing vaccines for SARS and Zika viruses were reallocated by federal funding agencies since the pandemic associated with these viruses were ended before vaccine development was completed. 25 

This review assimilates the search results of 1789 articles after preliminary screening conducted on PubMed, Google scholar, and web resources. Abstract and methodology screening were then performed and 1137 articles and documents were shortlisted. The flowchart of the final articles selection is illustrated in Figure 1 .

Furthermore, 424 articles and documents were excluded after the full-text screening, among them 49 articles were also in languages, other than English and 189 articles did not specify relevant results for a vaccine against SARS-CoV-2 coronavirus. During the process of SARS-CoV-2 infection, proteolytic processing of S-protein is occurred once host cell receptor protein angiotensin-converting enzyme 2 binds with C-terminus of S1-subunit of S-protein resulting in a protease activity which allows fusion of the virus to the host cell membrane. 12, [30] [31] [32] Most viral RNA act as pathogen-associated molecular patterns and detected by pattern recognition receptors, namely toll-like receptor (TLR) types 3, 7, 8, and 9 in the endosome. 12, 14, 33 Furthermore, RNA receptor retinoic-acid inducible gene I, cytosolic receptor melanoma differentiation-associated gene 5, and nucleotidyltransferase cyclic GMP-AMP synthase facilitate the cytosolic recognition of the virus. These complex signaling triggers downstream cascade molecules and activates NF-κB, IFN-α/β, and few proinflammatory cytokines. 12, 14, 34 Cytokines storm and dysregulated immune responses further induce respiratory disease pathogenesis caused by SARS-CoV-2 which is similar to SARS-CoV and MERS. In addition, the imbalances in levels of interleukins, GCSF, macrophages, colony-stimulating factor, interferons, and the complement system are reported in patients suffering from COVID-19. 8, 13, 35, 36 Large number of SARS-CoV-2 specific CD4 + and CD8 + T-cells subtypes were reported in COVID-19 convalescent patients. [37] [38] [39] However to envisage a larger perspective, cohort studies are needed to perform to examine whether the excess of T cells are protection or conversely associated with the pathogenesis of SARS-CoV-2 coronavirus. Therefore, these studies in understanding mechanistic F I G U R E 1 Flow diagram to illustrate selection criteria for the systematic review on COVID-19 vaccines

insights of COVID-19 pathogenesis, the outcome attributed to new vaccine intervention will be promising.

The vaccines are immune boosters against invading viruses by recognizing unique molecular candidates found on their surface or in the genome. Ideally, the human immune system responds against viral antigens by secreting proteins or special immune cells that 

For developing a vaccine against COVID-19 infection, a nonreplicating viral vector technology that is encoded by the process of antigen delivery through an unrelated vector shuttle is developed. This is a promising approach to induce immune response against the antigen non-replicating property of the vector. This process allows the vector to reproduce multiple copies causing vector to infect single cell, transmitting viral immunogens without causing viral infection. 57 

The replicating viral vector vaccine exploits the potential of vectors to continuously replicate and facilitate persistent immune response in the host cell. [68] [69] [70] Because of the properties of persistent responses through replicating viral vector vaccine, as compared with non-replicating viral vector vaccine, the viral vector vaccines promote longer and higher expression of immune cells even at lower immunization doses. [69] [70] [71] Though, similar to live attenuated vaccine, replicating viral vector vaccine can also revert to their virulence state. Therefore, utilization of replicating viral vector vaccine is still a major concern over regulatory guidelines considering their potential 

The inactivated vaccine consists of virus-like particles that have lost their pathogenicity but are still able to stimulate the human immune response. 73 

Protein subunit vaccines stimulate human immune response while presenting viral proteins, as a whole or otherwise, without any introducing viral vector. 79, 80 Similar to inactivated vaccines, subunit vaccines are also safe, do not risk for disease revert, however, good adjuvant need to be added for high immunogenicity. 79, 81, 82 Protein subunit and adjuvant based vaccine Table 1 .

The unavailability of effective treatment therapy for COVID-19 infection promotes the rapid development of several antiviral drugs which are still under clinical trials for potential outcomes. However, these trials will not predict the accurate safety and efficacy of the interventions in a short period of time. Therefore, it is inevitable to find accurate target proteins or respective biomarkers for rapid and market status in concern of SARS-CoV-2. An overview of probable immunogenic pathways is discussed with a particular focus on vaccine strategies targeting complex molecular interactions in- BT/IIPME0211/02/16) which are highly acknowledged.

The authors declare that there are no conflict of interests. 

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Utkarsh Jain http://orcid.org/0000-0003-3901-0153

Outbreak of pneumonia of unknown etiology in Wuhan

World-Health-Organization Coronavirus Disease (COVID-19) Outbreak

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Weekly Epidemiological and Operational updates

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

New and developing diagnostic platforms for COVID-19: a systematic review

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status

Novel coronavirus: where we are and what we know

The 2019 novel coronavirus disease (COVID-19) pandemic: a zoonotic prospective

Molecular immune pathogenesis and diagnosis of COVID-19

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses

Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more

Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and selfcontrolled case series study

Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: a scientific statement from the Indian Heart Rhythm Society

Therapeutic management of patients with COVID-19: a systematic review

Convalescent plasma as a potential therapy for COVID-19

Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Developing Covid-19 vaccines at pandemic speed

The COVID-19 vaccine development landscape

The SARS-CoV-2 vaccine pipeline: an overview

Consider TLR5 for new therapeutic development against COVID-19

Draft landscape of COVID-19 candidate vaccines

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-)

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Increased expression of CD8 marker on T-cells in COVID-19 patients

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases

SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options

Progress and prospects on vaccine development against SARS-CoV-2. Vaccines

The nucleocapsid protien of SARS-CoV-2: a target for vaccine development

Development of epitopebased peptide vaccine against novel coronavirus 2019 (SARS-CoV-2): immunoinformatics approach

Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS coronavirus-2 (SARS-CoV-2)

Frenkel-Morgenstern M. Immunoinformatics and structural analysis for identification of immunodominant epitopes in SARS-CoV-2 as potential vaccine targets

Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV

Comparison of DNA and mRNA vaccines against cancer

Nucleic acid nanoparticles at a crossroads of vaccines and immunotherapies

Lipid-based vectors for therapeutic mrna-based anti-cancer vaccines

An mRNA vaccine against SARS-CoV-2 -preliminary report

The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery

Lipid nanoparticle systems for enabling gene therapies

Lipid nanoparticles and their hydrogel composites for drug delivery: a review

Advances in mRNA vaccines for infectious diseases

mRNA vaccine delivery using lipid nanoparticles

Genetically Thermostabilised, immunogenic poliovirus empty capsids; a strategy for non-replicating vaccines

Early life vaccination: generation of adult-quality memory CD8+ T cells in infant mice using non-replicating adenoviral vectors

Simian adenoviruses as vaccine vectors

Universal influenza virus vaccines: what needs to happen next?

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector

Recombinant vector vaccine evolution

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-inhuman trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, doubleblind, placebo-controlled, phase 2 trial

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Replication-competent viral vectors for vaccine delivery

Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains

Replicating single-cycle adenovirus vectors generate amplified Influenza vaccine responses

Prolonged evolution of the memory B cell response induced by a replicating adenovirusinfluenza H5 vaccine

Measles-derived vaccines to prevent emerging viral diseases

A Live-attenuated prime, inactivated boost vaccination strategy with Chimeric Hemagglutininbased universal Influenza virus vaccines provides protection in ferrets: a confirmatory study

Poor antigen processing of poxvirus particles limits CD4 + T cell recognition and impacts immunogenicity of the inactivated vaccine

Live attenuated and inactivated influenza vaccine effectiveness

Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials

Development of an inactivated vaccine candidate for SARS-CoV-2

Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years

Subunit vaccines against emerging pathogenic human coronaviruses

Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications

Biotechnology approaches to produce potent, selfadjuvanting antigen-adjuvant fusion protein subunit vaccines

Recent advancements in combination subunit vaccine development

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M TM adjuvant in a phase I clinical trial

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses

Evaluation of Francisella Tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella Tularensis in a C57BL/6J mouse model

Live-attenuated vaccine against rsv generates robust cellular and humoral immune responses. Open Forum Infectious Diseases

Vaccine types. Kumar Vijay, Vaccine-History and future. IntechOpen

attenuated influenza vaccine: present and future roles

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

Design of a multiepitope-based peptide vaccine against the e protein of human COVID-19: an immunoinformatics approach

Genetic diversity and evolution of SARS-CoV-2

Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review